
Glenn Sabin Director of Strategy & Business Development, Cancer Commons and Author of n of 1
-
July 11, 2024
The Personalized Power of the “N-of-1” Approach
With:Randomized, controlled clinical trials with a large N—number of participants—are the recognized “gold standard” of evidence-based medicine. Even so, the results of large-N trials can only reveal population averages, and are not predictive of any individual’s response to a given treatment. On the other hand, one can consider every patient with cancer as the sole participant in their own clinical trial with an Nof1, even if the trial is not… Read more »